Buy 5 or More Products! Save 25% On Total.
 Buy 3 or More Products! Save 10% On Total.
 Free Shipping! No Minimum Order.

Dayvigo (Lemborexant) is indicated for the treatment of insomnia. The probable mechanism of action of Dayvigo (Lemborexant) is:

a. benzodiazepine receptor agonist
b. benzodiazepine receptor antagonist
c. Melatonin receptor agonist
d. Orexin receptor antagonist
e. Histamine H2 receptor antagonist

Answer: (d) The active ingredient found in Dayvigo (Lemborexant) is Lemborexant. Each film coated tablet contains 5 mg or 10 mg of Lemborexant.

Dayvigo (Lemborexant) is indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.

The recommended dosage of Dayvigo (Lemborexant) is 5 mg taken no more than once per night, immediately before going to bed, with at least 7 hours remaining before the planned time of awakening.

The dose may be increased to the maximum recommended dose of 10 mg based on clinical response and tolerability. Time to sleep onset may be delayed if taken with or soon after a meal.

The mechanism of action of Dayvigo (Lemborexant) in the treatment of insomnia is presumed to be through antagonism of orexin receptors. The orexin neuropeptide signaling system plays a role in wakefulness.

Blocking the binding of wake-promoting neuropeptides orexin A and orexin B to receptors OX1R and OX2R is thought to suppress wake drive. Dayvigo (Lemborexant) binds to orexin receptors OX1R and OX2R and acts as a competitive antagonist.

Somnolence, headache, fatigue and abnormal dreams are reported side effects of drug.

Try our Naplex QBank. **Please note: This type of question will not show up in an MPJE. We are just posting to MPJE group for knowledge.